HUMAN SARS CoV-2 SPIKE PROTEIN MUTATIONS

Lalitha Guruprasad, School of Chemistry, University of Hyderabad, Hyderabad 500046, India

Email: lalitha.guruprasad@uohyd.ac.in

ABSTRACT

The human SARS-CoV-2 spike protein sequences from Asia, Africa, Europe, North America, South America and Oceania were analyzed by comparing with the reference SARS-CoV-2 protein sequence from Wuhan-Hu-1, China. Out of 10,333 spike protein sequences analyzed, 8,155 proteins comprised one or more mutations. A total of 9,654 mutations were observed that correspond to 400 distinct mutation sites. The receptor binding domain (RBD) which is involved in the interactions with human ACE-2 receptor and causes infection leading to the COVID-19 disease comprised 44 mutations that included residues within 3.2 Å interacting distance from the ACE-2 receptor. The mutations observed in the spike proteins are discussed in the context of their distribution according to the geographical locations, mutation sites, mutation types, distribution of the number of mutations at the mutation sites and mutations at the glycosylation sites. The density of mutations in different regions of the spike protein sequence and location of the mutations in protein three-dimensional structure corresponding to the RBD are discussed. The mutations identified in the present work are important considerations for antibody, vaccine and drug development.

KEYWORDS: SARS-CoV-2, Spike proteins, receptor binding domain, mutations, sequence and structural mapping
INTRODUCTION

The epicentre of the ongoing COVID-19 pandemic caused by the human SARS-CoV-2 was first identified in the city of Wuhan-Hubei-1 province, China during mid-December 2019 (Wu et al., 2020). Since then, the disease has spread rapidly and has affected millions of people in the populations worldwide leading to more than 778,102 deaths until date (https://www.worldometers.info/coronavirus/). The SARS-CoV-2 belongs to the family of Coronaviridae, subfamily of Orthocoronavirinae and genera of β-CoV (https://www.ncbi.nlm.nih.gov/taxonomy/694009). The spread of the disease is attributed to contact via respiratory droplets either due to coughing or sneezing or through surface contact. As on date, no vaccines or specific drugs are available to treat the disease, however, there is enormous ongoing efforts worldwide in this direction.

The SARS-CoV-2 is a spherical shaped virion with a positive-stranded RNA viral genome of size 30 kb that is translated into structural and non-structural proteins. The spike glycoprotein is a homotrimer present on the surface of the coronavirus that plays a vital role in recognition of human host cell surface receptor ACE-2 (Zhang et al., 2020). This recognition is required for fusion of viral and host cellular membranes for transfer of the viral nucleocapsid into the host cells. SARS-CoV-2 is reported to have originated in bats (Zhou et al., 2020) and subsequently transmitted to humans via pangolins as intermediate host species (Han 2020, Lam et al., 2020, Guruprasad 2020a, communicated). In order to be able to jump species and infect a new mammalian host, the viral genome undergoes several mutations specifically in the spike proteins.

The spike protein comprises an N-terminal S1 subunit and a C-terminal membrane proximal S2 subunit. The S1 subunit consists S1\textsuperscript{A}, S1\textsuperscript{B}, S1\textsuperscript{C} and S1\textsuperscript{D} domains. The S1\textsuperscript{A} domain, referred as N-terminal domain (NTD), recognises carbohydrate, such as, sialic acid required for attachment of the virus to host cell surface. The S1\textsuperscript{B} domain, referred as receptor-binding domain (RBD) of the SARS-CoV-2 spike protein interacts with the human ACE-2 receptor (Zhang et al., 2020, Wang et al., 2020). The structural elements within the S2 subunit comprises three long α-helices, multiple α-helical segments, extended twisted β-sheets, membrane spanning α-helix and an intracellular cysteine rich segment. The PRRA sequence motif located between the S1 and S2 subunits in SARS-CoV-2 presents a furin-cleavage site.
In the S2 subunit, a second proteolytic cleavage site S2′, upstream of the fusion peptide is present. Both these cleavage sites participate in the viral entry into host cells.

In a study on the infectivity and reactivity to a panel of neutralizing antibodies and sera from convalescent patients, Li et al., (2020) have reported mutations and glycosylation site modifications in human SARS-CoV-2 spike proteins. Few mutations have been reported in the spike glycoprotein (Kaushal et al., 2020). The D614G mutation is reported to be relatively more common (Korber et al., 2020, Phelan et al., 2020, Mercatelli and Giorgi 2020, Guruprasad, 2020a) and is known to increase the efficiency of causing infection (Zhang et al., 2020). Mutation sites for spike proteins from some of the SARS-CoV-2 Indian isolates have been mapped on to protein three-dimensional structure (Guruprasad, 2020b, Yadav et al., 2020, Saha et al., 2020).

In light of the large number of SARS-CoV-2 spike protein sequences currently available in the NCBI virus database, we intended to carry out an exhaustive analysis, in order to understand the current scenario of mutations in the spike proteins. Our study informs us of all the mutations present in the human SARS-CoV-2 spike proteins relative to Wuhan-Hu-1 reference sequence from China, according to their geographical locations, positions of the mutation sites, distribution of the number of mutations at the mutation sites, the different mutation types observed so far, mutations at glycosylation sites, occurrence of multiple mutations in a single spike protein and mutations within the RBD close to the host-cell ACE-2 receptor interactions. Our study has implications from the perspective of vaccine, antibody and drug design.
METHODS

The SARS CoV-2 spike protein sequences were obtained in the FASTA format from the NCBI virus database (https://www.ncbi.nlm.nih.gov/labs/virus/vssi/). The multiple sequence alignment of the proteins was achieved using NGPhylogeny server (http://www.NGPhylogeny.fr) (Katoh and Standley 2013, Lemoine et al., 2019). The human SARS-CoV-2 spike protein sequence from Wuhan-Hu-1, China (NCBI accession code: YP_009724390.1) (Wu et al., 2020) was used as reference sequence to examine the mutations. The identification of mutations in the spike proteins and further analyses was carried out using the software suite of programs developed by ABREAST™ (https://www.abreast.in). The mutations were analyzed according to their presence within different regions of the spike protein sequence. The locations of mutations in RBD (S1B domain) of the spike protein were mapped on to the three-dimensional crystal structure available in the Protein Data Bank (PDB) (Berman et al., 2000) (PDB code: 6LZG) (Wang et al., 2020). The molecular visualization was carried out using PyMol (DeLano 2002).
RESULTS AND DISCUSSIONS

**Worldwide distribution of mutations in spike protein**

The NCBI virus database contained 10,333 SARS-CoV-2 spike proteins that were analyzed. These represented spike proteins from Africa (103), Asia (996), Europe (370), North America (8,268), South America (29) and Oceania (567). The length of protein sequences ranged between 1250 - 1273 amino acid residues. One or more amino acid mutations were observed in 8,155 proteins. A total of 9,654 mutations were observed corresponding to 400 distinct mutation sites. The distribution of total number of mutations in spike proteins analyzed from different geographical locations is shown in Table 1. The large number of spike protein sequences available has provided an opportunity to evaluate the wide-spectrum of mutations observed across the continents of the world. The mutations analysed are a result of human-to-human transmission of the virus since January 2020.

**Distribution of the number of mutations at mutation sites in the spike protein sequence**

Nearly one-third of the spike protein sequence is associated with mutations. The list of the mutation sites along with total number of mutations observed at individual mutation sites is shown in Supplementary Table 1. The top ten mutation sites according to the total number of occurrences were; D614(7859), L5(109), L54(105), P1263(61), P681(51), S477(47), T859(30), S221(28), V483(28), A845(24).

**Mutation density in different regions of the spike protein sequence**

The distribution of the mutations within different regions of the spike protein is shown in Table 2. Mutations are distributed in almost all regions of the protein. The S1D domain (594-674) that comprises the D614G mutation is the most predominant and is observed in 7,859 of the 7915 mutations in this region of the spike protein. Our analysis is in agreement with the high frequency of D614G mutation in the spike proteins or the more common occurrence as reported previously (Korber, 2020, Phelan et al., 2020, Mercatelli and Giorgi 2020, Guruprasad, 2020a). The mutation density evaluated as a function of the number of unique mutations observed for sequence length corresponding to the different regions in the spike
protein is shown in Figure 1. The protease cleavage site (between residues 675-692) in the spike protein is associated with the maximum mutation density. The mutations at this site in the spike protein may be of advantage for the virus to undergo proteolytic cleavage by a large number of host enzymes in its evolution. Further, the NTD (S1\(^\Delta\) domain) is another region where mutations have accumulated relatively more in number compared with rest of the spike protein.

**Human SARS-CoV-2 spike protein mutation sites and mutation types**

More than one mutation type can be found at the same position in the spike protein sequence. For instance, at position 88 the amino acid residue D is observed to be mutated either to N, E, Y or A. At position 675, the amino acid residue Q is mutated either to R, H, K or is deleted among the spike proteins. The geographical location-wise distribution of the unique mutation sites and unique mutation types is shown in Table 3. Accordingly, the total number of unique mutation sites observed were; North America (300), South America (4), Europe (42), Africa (16), Asia (166) and Oceania (51) and the total number of unique mutation types observed were; North America (350), South America (4), Europe (43), Africa (16), Asia (181) and Oceania (51). It is clear from our study that the human SARS-CoV-2 spike protein undergoes mutations at multiple sites and there can be more than one mutation type associated with a mutation site. The D614G is the only mutation, that has so far been commonly observed among the spike proteins from all the continents. Table 3 serves as a reference to consult the presence or absence of a particular mutation within and between the various continents.

**Mapping mutations in receptor-binding domain of SARS-CoV-2 spike protein**

The spike protein plays a vital role for the attachment to host cell-surface specific receptors and subsequently catalyzes the virus - host cell membrane fusion required for causing infection. The RBD in spike protein interacts with host ACE-2 receptor to cause the novel coronavirus infection leading to COVID-19 disease. The three-dimensional crystal structure of human SARS-CoV-2 RBD (between residues 333-527) complexed with the ACE-2 receptor (PDB code: 6LZG) was used to map the mutation sites as shown in Figure 2. The RBD of human SARS COV-2 spike proteins from different continents is associated with 44 distinct mutation sites. The mutations are located at positions; 337, 344, 345, 348, 354, 357,
The numbers marked in bold indicate instances of more than 10 occurrences of the mutations observed at the particular position. The numbers underlined indicate instances of more than 5 occurrences of the mutations observed at the particular position. The distribution of the number of mutations in RBD observed at the 44 different positions is shown in Figure 3. The mutation sites and mutation types of the human SARS-CoV-2 spike protein in the RBD according to the geographical location-wise distribution is included in Table 3. Accordingly, the total number of unique mutation sites observed were; North America (27), South America (0), Europe (7), Africa (1), Asia (15) and Oceania (9) and the total number of unique mutation types observed were; North America (28), South America (0), Europe (7), Africa (1), Asia (16) and Oceania (9). The mutations occurring in relatively large numbers in RBD were examined. A maximum of forty-seven mutations were observed at position 477 in the RBD of the spike protein. The S477N mutation was present in 45 spike proteins from Oceania, 1 from Asia (NCBI ID: QLR12405.1) and 1 from North America (NCBI ID: QMU91291.1). The V483A mutation was observed in 27 spike proteins representative of North America and one spike protein from Oceania (QLG76529.1) contained a mutation at the same position, but with mutation type V483F. The A344S mutation was observed 18 times and all the associated spike proteins were representative of North America.

Some of the residues in the spike protein RBD that are involved in the interactions with the ACE-2 receptor are mutated as shown in Figure 4. The residues in spike protein RBD that are $\leq 3.2$ Å inter-atomic distance from the ACE-2 receptor as observed in the crystal structure of the human SARS CoV-2 spike protein RBD complexed with ACE-2 receptor (PDB code: 6LZG) are; K417, Y449, Y453, A475, N487, T500, N501 and G502. The Y453 residue in spike protein RBD is close to His34 in ACE-2 receptor and T500 and N501 residues in spike protein RBD are close to Tyr41 in ACE-2. Few residues close to the residues that are $\leq 3.2$ Å from the ACE-2 receptor are also associated with the mutations. These residues are G476 (next to A475), F486 (next to N487) and G502 (next to N501).

Mutations were observed for the residues Y453, T500, N501. The Y453F mutation is present in 5 spike proteins from Europe (NCBI accession codes: QJS39603.1, QJS39579.1, QJS39543.1, QJS39591.1, QJS39555.1). The T500I mutation is present in the spike protein
from Oceania (QLG75833.1). The N501Y mutation is present in 14 spike proteins from Oceania (QLG76793.1, QLG76805.1, QLG76817.1, QLG76085.1, QLG76181.1, QLG76685.1, QLG76697.1, QLG76709.1, QLG76277.1, QLG76097.1, QLG76745.1, QLG76685.1, QLG76697.1, QLG76709.1, QLG76277.1, QLG76097.1, QLG76745.1, QLG76685.1, QLG76697.1, QLG76709.1, QLG76277.1, QLG76097.1, QLG76745.1, QLG76685.1, QLG76697.1, QLG76709.1, QLG76277.1, QLG76097.1, QLG76745.1) and the N501T mutation is present in the spike proteins from Europe (QJS39507.1). The G476S mutation is present in eight spike proteins from North America (NCBI accession codes: QIS30425.1, QIS30625.1, QKS90479.1, QIQ49882.1, QKS90179.1, QIC20487.1, QJC20487.1, QJD48075.1) and the one F486L mutation in the spike protein from Europe (NCBI accession codes: QJS39567.1).

Therefore, residues at positions; 453, 476, 486, 500, 501 that are associated with the RBD mutations and that are close to the ACE-2 receptor would affect the shape and charge of the protein near the protein-receptor interaction interface. However, despite these mutations in the RBD of human SARS-CoV-2 spike protein, the novel coronavirus causes the infection leading to COVID-19 disease. The regions of protein-protein interactions between virus and host are being targeted as sites for drug design and the spike protein and epitopes are the ideal targets for vaccine design. Therefore, changes in the shape of the protein surface due to the mutations, especially near the protein-receptor binding regions would be important considerations for antibody, vaccine and drug development.

**Spike protein sequences with multiple mutations**

The 8,155 spike proteins comprise anywhere between 1 to 16 mutations. The spike proteins containing 8 or more mutations in the same protein are discussed below. The spike protein with 16 mutations (QMS95041.1) corresponds to the SARS-CoV-2 isolated on 1st May 2020 from Iran, Asia. The mutations; H146R, R190S, G268D, P337R, L368P, A411D, Q607L, D614G, A672D, Q774R, G798A, S974P, S1147L, R1185H, V1230E, G1246A are located at different positions that lie scattered in the spike protein. The protein (QKN61229.1) isolated on 18th March 2020 from Taiwan has two regions of inframe deletions; 68-76 corresponding to the NTD domain and 675-679 corresponding to the protease cleavage site. The protein (QKS67443.1) isolated in March 2020 from Hong Kong has 11 mutations between residues 679-688 also within the protease cleavage site and a V367F mutation in RBD. The protein (QJD23249.1) isolated 20th March 2020 from Malaysia has 8 mutations; between residues 292-297 in NTD and two mutations; P491L and H519Q in RBD.
**Spike proteins not associated with mutations**

We observed 2,178 spike proteins that do not show any mutations relative to the human SARS-CoV-2 spike protein RefSeq from Wuhan-Hu-1, China. Interestingly, some of the human SARS-CoV-2 genomes isolated during June 2020 have not undergone any mutation yet. These include 42 spike protein sequences from North America (NCBI accession codes: QMT50797, QMT51409, QMT51505, QMT51865, QMT52129, QMT52237, QMT52249, QMT52393, QMT52561, QMT52741, QMT52765, QMT53017, QMT53041, QMT53053, QMT53065, QMT53089, QMT53101, QMT53149, QMT53173, QMT53197, QMT53211, QMT53233, QMT53245, QMT55880, QMT57260, QMT57332, QMT57572, QMT57584, QMT57608, QMT57644, QMT57656, QMT57692, QMT94108, QMT94756, QMT94780, QMT95200, QMT95308, QMT95356, QMT95368, QMT95452, QMT95488, QMT95560), 5 from Asia (QLL26046, QLI49781, QLF98260, QKY60061, QKV26077) and 2 from Africa (QKR84420, QKS66940).

**Glycosylation site mutations**

The NxT/S represent glycosylation site sequence motifs. The deletions at glycosylation sites; N331 and N343 in the spike proteins are known to have caused lesser infections revealing the importance of glycosylation for viral infectivity (Li et al., 2020). The examination of three-dimensional electron microscopy structures of human SARS-CoV-2 spike proteins (PDB code: 6VSB) on the graphics showed a number of glycosylation sites in the human SARS-CoV-2 spike protein. We observed instances of the SARS-CoV-2 spike proteins where either the N or the S/T in the NxT, NxS sequence motifs were mutated. The spike proteins from North America; (NCBI accession code: QKU31901.1) is associated with N17K mutation and (QKV40463.1) is associated with T1136I mutation that is glycosylated at N1134. The spike proteins from Asia; (QLG99547.1) is associated with S151I mutation and (QLA46612.1) with S151G mutation and these spike proteins are glycosylated at N149.
CONCLUSIONS

The human SARS-CoV-2 spike proteins comprise 400 distinct mutation sites with reference to the first human SARS-CoV-2 sequence from Wuhan-Hu-1, China. The mutations are present in 8155 proteins among 10,333 human SARS-CoV-2 spike protein sequences analysed in the present work. The total number of mutations observed were 9,654 for all the spike proteins. The mutation sites are distributed over whole length of the protein sequence with the maximum mutation density being near the protease cleavage site between residues 675-692. The RBD is associated with 44 mutation sites and within the RBD, the mutations; S477N, V483A, A344S, N501Y were more frequent. The D614G mutation is predominant and is the only common mutation observed so far among all the continents. Some of the SARS-CoV-2 spike proteins are associated with the mutations at glycosylation sites. Nearly, 21% SARS-CoV-2 spike proteins have not undergone any mutations yet with respect to the first human SARS-CoV-2 Wuhan-Hu-1 reference sequence that became available during December 2019. Within the RBD, mutations were observed for Y453, G476, F486, T500, N501 that are close to the ACE-2 receptor. The mutations present at the interface between the spike protein and ACE-2 receptor could potentially affect vaccine performance and drugs designed at the interface of protein-protein interactions. Therefore, the mutations identified in the present work would be important considerations for antibody, vaccine, and drug development.
ACKNOWLEDGEMENTS

LGP thanks School of Chemistry, University of Hyderabad for research facilities and ABREAST™ (https://www.abreast.in) for making available the computer programs used in this work for the identification and analyses of the mutations.

CONFLICT OF INTEREST

The author declares no conflict of interest

FUNDING

None
REFERENCES

Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N. and Bourne, P.E., 2000. The protein data bank. *Nucleic acids research*, 28(1), pp.235-242.

DeLano, W.L., 2002. Pymol: An open-source molecular graphics tool. *CCP4 Newsletter on protein crystallography*, 40(1), pp.82-92.

Guruprasad, K. (2020a). Amino acid mutations in the protein sequences of human SARS CoV-2 Indian isolates compared to Wuhan-Hu-1 reference isolate from China. ChemRxiv.

Guruprasad, K. (2020b). Mapping mutations in proteins of SARS CoV-2 Indian isolates on to the three-dimensional structures. ChemRxiv.

Guruprasad, L. (2020). Human coronavirus spike protein-host receptor recognition. Communicated.

Han, G.Z., 2020. Pangolins Harbor SARS-CoV-2-Related Coronavirus. *Trends in Microbiology*.

Katoh, K. and Standley, D.M., 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Molecular biology and evolution*, 30(4), pp.772-780.

Kaushal, N., Gupta, Y., Goyal, M., Khaiboullina, S.F., Baranwal, M. and Verma, S.C., 2020. Mutational Frequencies of SARS-CoV-2 Genome during the Beginning Months of the Outbreak in USA. *Pathogens*, 9(7), p.565.

Korber, B., Fischer, W.M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E.E., Bhattacharyya, T., Foley, B. and Hastie, K.M., 2020. Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell*. 
Lam, T.T.Y., Jia, N., Zhang, Y.W., Shum, M.H.H., Jiang, J.F., Zhu, H.C., Tong, Y.G., Shi, Y.X., Ni, X.B., Liao, Y.S. and Li, W.J., 2020. Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins. *Nature*, pp.1-4.

Lemoine, F., Correia, D., Lefort, V., Doppelt-Azeroual, O., Mareuil, F., Cohen-Boulakia, S. and Gascuel, O., 2019. NGPhylogeny. fr: new generation phylogenetic services for non-specialists. *Nucleic acids research*, 47(W1), pp.W260-W265.

Li Q, Wu J, Nie J, et al. The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity *Cell*. 2020; S0092-8674(20)30877-1. doi:10.1016/j.cell.2020.07.012

Mercatelli, D. and Giorgi, F.M., 2020. Geographic and Genomic Distribution of SARS-CoV-2 Mutations. Preprints.

Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J. and Xiang, Z., 2020. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. *Nature communications*, 11(1), pp.1-12.

Phelan, J., Deelder, W., Ward, D., Campino, S., Hibberd, M.L. and Clark, T.G., 2020. Controlling the SARS-CoV-2 outbreak, insights from large scale whole genome sequences generated across the world. *BioRxiv*.

Saha, P., Banerjee, A.K., Tripathi, P.P., Srivastava, A.K. and Ray, U., 2020. A virus that has gone viral: amino acid mutation in S protein of Indian isolate of Coronavirus COVID-19 might impact receptor binding, and thus, infectivity. *Bioscience Reports*, 40(5).

Wang, Q., Zhang, Y., Wu, L., Niu, S., Song, C., Zhang, Z., Lu, G., Qiao, C., Hu, Y., Yuen, K.Y. and Wang, Q., 2020. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. *Cell*.

Wu, F., Zhao, S., Yu, B., Chen, Y.M., Wang, W., Song, Z.G., Hu, Y., Tao, Z.W., Tian, J.H., Pei, Y.Y. and Yuan, M.L., 2020. A new coronavirus associated with human respiratory disease in China. *Nature*, 579(7798), pp.265-269.
Yadav, P.D., Potdar, V.A., Choudhary, M.L., Nyayanit, D.A., Agrawal, M., Jadhav, S.M., Majumdar, T.D., Shete-Aich, A., Basu, A., Abraham, P. and Cherian, S.S., 2020. Full-genome sequences of the first two SARS-CoV-2 viruses from India. *The Indian journal of medical research, 151*(2-3), p.200.

Zhang, H., Penninger, J.M., Li, Y., Zhong, N. and Slutsky, A.S., 2020. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. *Intensive care medicine, 46*(4), pp.586-590.

Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang, C.L. and Chen, H.D., 2020. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature, 579*(7798), pp.270-273.
Figure 1. Mutation density in human SARS-CoV-2 spike protein regions
FIGURE 2. The 44 mutations (red spheres) mapped on to the crystal structure of the spike protein RBD (cyan) complexed with ACE-2 receptor (green) (PDB code: 6LZG).
FIGURE 3. Mutations in human SARS-CoV-2 spike protein RBD
FIGURE 4. Interactions of spike protein residues (cyan) with ACE2 (green) side-chain residues (yellow) that are within 3.2Å in crystal structure of human SARS-CoV-2 spike protein RBD complexed with ACE-2 receptor (PDB code: 6LZG). The spike protein mutated residues are shown in (red).
Table 1. Geographical distribution of human SARS-COV-2 spike proteins and their associated number of mutations

| Continent       | Number of spike proteins | Number of mutations |
|-----------------|--------------------------|---------------------|
| Africa          | 103                      | 121                 |
| Asia            | 996                      | 1169                |
| Europe          | 370                      | 360                 |
| North America   | 8268                     | 7453                |
| South America   | 29                       | 26                  |
| Oceania         | 567                      | 525                 |
Table 2. Distribution of mutations in the different regions of human SARS-CoV-2 spike proteins

| Regions                                      | Total number of mutations | Number of distinct mutation types |
|----------------------------------------------|---------------------------|-----------------------------------|
| S1\(^\AA\) domain (1-302)                    | 759                       | 196                               |
| S1\(^\AA\)-S1\(^\BB\) linker (303-332)       | 31                        | 11                                |
| S1\(^\BB\) domain (333-527)                  | 204                       | 52                                |
| S1\(^\BB\) - S1\(^\CC\) linker (528-533)     | 1                         | 1                                 |
| S1\(^\CC\) domain (534-589)                  | 75                        | 15                                |
| S1\(^\CC\) - S1\(^\DD\) linker (590-593)    | 0                         | 0                                 |
| S1\(^\DD\) domain (594-674)                  | 7915                      | 34                                |
| Protease cleavage site (675-692)             | 126                       | 35                                |
| S1-S2 subunits linker (693-710)              | 13                        | 7                                 |
| Central β-strand (711-737)                   | 13                        | 7                                 |
| Downward helix (738-782)                     | 24                        | 18                                |
| S2’ cleavage site (783-815)                  | 27                        | 13                                |
| Fusion peptide (816-828)                     | 6                         | 3                                 |
| Connecting region (829-911)                  | 111                       | 26                                |
| Heptad repeat region (912-983)               | 73                        | 18                                |
| Central helix (984-1034)                     | 8                         | 6                                 |
| β-hairpin (1035-1068)                        | 7                         | 4                                 |
| β-sheet domain (1069-1133)                   | 79                        | 27                                |
| Heptad repeat region (1134-1213)             | 65                        | 22                                |
| Transmembrane region (1214-1236)             | 28                        | 7                                 |
| Cytoplasmic region (1237-1273)               | 89                        | 15                                |
Table 3. Mutations sites and mutation types observed in human SARS-CoV-2 spike proteins according to the geographical locations

| North America | F2L, L5F, L5I, V6F, L7V, P9L, S12C, Q14H, C15F, N17K, L18F, T20I, T22N, T22A, T22I, Q23K, P25S, A27S, A27V, T29I, F32L, R34C, H49Y, S50L, T51I, Q52L, Q52H, L54F, L54W, F55I, P57L, H69Y, S71F, G72V, T73I, G75V, T76I, F79L, D80N, D80Y, N87Y, D88N, D88E, D88Y, D88A, V90F, T95A, T95I, E96D, K97T, S98F, R102I, I105L, D111N, K113R, L118F, V130A, E132D, C136R, D138H, L141F, L141L, L141V, L141F, G142V, G142S, G142D, Q239R, T240I, L242F, A243S, A243V, H245R, H245Y, R246K, D253Y, D253G, S254F, S256L, W258L, G261V, G261A, R262S, W265C, V267L, R273S, E281Q, A288S, L293V, D294E, S295S, G298R, T307I, V308L, E309Q, Q314K, Q314L, Q314F, T315I, Q321L, T322I, P330S, A344S, T345S, A348T, A348S, N354K, R357K, V367F, V382L, P384L, V395I, R403K, V407I, A411S, G413R, L441F, R457K, K458Q, G476S, S477N, P479L, V483A, E484Q, Q493L, S494P, Y508H, H519Q, A520S, A522V, K529E, G545S, T547I, L552F, E554D, K558N, A570V, T572I, D574Y, E583D, I584V, S596I, I584V, N603H, Q613H, D614G, V615F, T618A, P621S, V622F, V622I, V622A, A623S, H625Y, A626V, P631S, W633R, G639V, S640F, A647S, A647V, E654Z, E645K, H655Y, N608Y, A668S, A672V, Q675R, Q675H, T676S, T676L, Q677H, Q677R, T678I, P681L, P681H, R682W, A684S, A684T, V687L, A688V, A688S, S689I, S689L, S691F, S698L, N703D, S704L, V705F, A710V, I714M, T716I, I720V, T724A, M731I, T732A, T732I, G744V, V745S, N751D, L754F, R765S, R765H, T768I, G769A, A771S, T778I, Q779H, E780Q, A783S, D808V, D808G, P809S, I818V, L822F, D830H, D830Y, Q836P, Q836L, G838D, Q845S, E845Q, A845Q, A846V, R847I, K854R, N856S, T859I, D867N, A879V, A879S, A893E, A893V, E918V, L922F, A924S, A924V, S929I, D936H, D936Y, L938F, S939F, T941I, G946V, A958S, N969S, L981F, T1006, V1008T, T1009I, A1016S, A1020V, F1052L, P1053T, L1063F, V1065L, A1070V, Q1071I, E1072V, K1073N, A1078V, A1078S, G1085R, K1086N, R1091L, H1101Y, V1104L, P1112L, D1118Y, T1120I, V1122L, S1123P, G1124V, R1129A, I1130M, T1136I, D1139H, L1141F, D1146H, S1147L, D1153Y, P1162Q, I1162S, P1162Q, P1162S, D1163Y, G1167V, D1168H, V1176F, N1187Y, K1191N, N1192T, E1195Q, L1203F, K1205N, E1207A, L1219V, G1219S, I1221T, V1228L, M1229I, V1230L, T1231I, T1231A, C1235F, M1237L, M1237V, M1237T, T1238I, K1245N, C1247F, G1251R, D1259H, S1261F, P1263L, V1264L |
| Region          | Variants                                                                 |
|-----------------|--------------------------------------------------------------------------|
| South America   | N74K, I197V, D614G, V1176F                                               |
| Europe          | L5F, T22I, H49Y, Q115R, M153I, L176I, L176F, F186S, N188D, I197V, V213L, T240I, S254F, G261D, V367F, C379F, V382E, T393P, Y453F, F486L, N501T, T553N, K558R, T572I, L611F, D614G, T676I, S686G, M740I, G769V, Y789D, F797C, D839Y, A845S, A1020V, H1101Y, V1122L, P1162L, K1191N, M1229I, D1260N, D1260H, P1263L |
| Africa          | L5F, S12F, T29I, H49Y, V70F, Y144-, L242F, A288T, Q314R, R408I, A570S, D614G, S640A, A653V, Q677H, P812L |
| Asia            | F2L, L5F, L8V, S12F, S13I, Q14H, T22I, P25L, Y28H, Y28N, T29A, G35V, Y38C, H49Y, S50L, L54F, A67V, A67S, I68-, I68R, H69-, V70-, S71-, G72-, T73-, N74-, N74K, G75V, G75-, T76I, T76-, R78M, F86S, T95I, E96G, K97Q, S98F, V127F, D138Y, D138H, F140L, L141-, G142-, V143-, Y144-, H146Y, H146R, N148Y, S151G, W152L, M153I, S155I, E156D, S162I, Q173H, M177I, G181A, N185K, R190S, N211Y, V213L, S221W, Y248H, S255F, W258L, G261R, G261S, A262S, V267L, G268D, Q271R, A292V, L293M, D294I, P295H, L296F, S297W, C301F, P337R, V367F, L368P, V382L, R408I, A411D, E471Q, S477N, E484Q, P491L, Q506H, P507H, P507S, Y508N, L518I, H519Q, A520S, A570V, T572I, D574Y, E583D, G594S, Q607L, Q613H, D614G, V622F, A653V, E654Q, H655Y, Y660F, A672D, Q675-, Q675H, Q675R, T676-, Q677H, Q677-, T678-, N679-, S680-, P681-, R682Q, R682W, R682-, A684V, A684-, R685-, S686-, V687-, A688V, A688-, Q690H, A701V, A706S, M731I, L754F, R765L, A771S, V772I, Q774R, E780D, A783S, K786N, T791I, K795Q, G798A, P809S, T827I, A829T, I834V, A879S, S884F, A892V, M900I, A930V, D936Y, L938F, S939F, S939Y, S974P, Q1002E, L1063F, T1077I, H1083Q, D1084Y, H1088R, F1089V, V1104L, F1109L, D1139Y, S1147L, D1153Y, G1167S, K1181R, R1185H, N1187K, K1191N, E1195Q, Q1201K, V1230E, C1243F, G1246A, D1259Y |
| Oceania         | L5F, T22I, T29I, H49Y, S50L, T76I, S98F, I128F, D138H, M153I, L176F, D178N, E180K, I210-, S221L, S247R, D253G, W258L, A262T, G283V, I468T, E471Z, S477N, V483F, G485R, Q498Z, T500I, N501Y, H519Q, P561L, E583D, D614G, P621S, A626V, Q675K, Q675H, S704L, M731I, T791I, D808B, P812S, D839N, A846V, I931V, D936Y, K1073N, 1079S, G1124V, D1163G, C1254F, D1260N |